Company summary
CVS Group is a veterinary-services business operating first-opinion practices, specialist referral centres and related services. Its UK network is complemented by a growing Australian business.
← Back to the 350
CVSG
CVS Group
Health Care
- Index
- FTSE 250
- ISIN
- Not specified
- Book status
- 2026 edition — current
Key activities
Veterinary consultations and surgery, specialist referral services, diagnostics, laboratories, pet crematoria, online pharmacy and associated pet-care services.
Key markets
The United Kingdom is the core market, with Australia providing a growing second platform. Customers are primarily companion-animal owners, with some equine and farm-animal activity.
Key drivers
Pet ownership, pricing and visit volumes, recruitment and retention of vets, clinical capacity, acquisitions, expansion in Australia, diagnostic and referral growth and operational efficiency.
Key risks
Veterinary-sector regulation, competition scrutiny, wage inflation, shortages of veterinary professionals, consumer affordability, acquisition integration and reputational risk around pricing and treatment practices.
Recent Developments
23 July 2026: CVS said FY2026 revenue rose 5.9% to £712.8m. Australia generated £79.1m of revenue and has become a meaningful second platform, while the group continues to respond to proposed UK veterinary-market reforms.
Dividend notes
CVS normally considers an annual dividend after full-year results. As at 14 August 2026 the FY2026 dividend had not yet been declared; preliminary results are scheduled for September, so the amount and ex-dividend timetable should be checked then.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.